Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL ← Incidence and survival impact of self-reported symptom and psychological distress among patients with multiple myelomaThe American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Database: Characteristics and Methods →
